缺血性与非缺血性心肌病中的心肌成纤维细胞活化
这项前瞻性病例对照研究纳入81名参与者,用[68Ga]FAPI-46 PET/MRI评估成纤维细胞活化。心衰患者心肌摄取均高于健康志愿者,缺血性心肌病摄取最高且局限于梗死区,非缺血性心肌病呈弥漫性较低强度摄取,基线摄取较高与射血分数改善较少相关。
要点
- 心衰患者心肌成纤维细胞活化持续存在,缺血性与非缺血性心肌病空间分布模式不同
- 缺血性心肌病摄取最高并定位于既存梗死区,非缺血性心肌病呈弥漫低强度且基底间隔信号最高
- 基线[68Ga]FAPI-46摄取较高与优化药物治疗后射血分数改善较少相关
核心结论
- 心衰患者存在持续的心肌成纤维细胞活化,且空间模式因心肌病病因不同而异,无创成纤维细胞活化成像可能有助于机制认识、风险分层及靶向抗纤维化治疗研发。
研究设计与样本
- 前瞻性病例对照研究,共纳入81名参与者(平均[SD]年龄66.2[9.7]岁,22[27%]为女性),包括42例射血分数降低的心衰患者(21例缺血性心肌病、21例非缺血性病因,平均[SD]左室射血分数41%[9%])、20例既往心梗但左室收缩功能保留者及19名健康志愿者,部分心衰患者间隔超过6个月复查影像。
主要发现
- 健康志愿者未见心肌成纤维细胞活化;全部心衰患者心肌[68Ga]FAPI-46摄取高于健康志愿者(平均[SD] SUVmax 2.7[1.5] vs 1.5[0.3];P < .001)。
- 缺血性心肌病摄取最高,定位于既存心肌梗死区域(平均[SD] SUVmax 3.2[1.1])。
- 非缺血性心肌病表现为弥漫、较低强度摄取(平均[SD] SUVmax 2.3[0.5]),无论晚期钆增强如何,基底间隔信号最高。
- 缺血性心肌病摄取高于既往心梗无心衰者(n = 20),尽管梗死面积无主要差异(平均[SD] SUVmax 3.2[1.1] vs 2.5[0.3];P = .03)。
- 复查影像的心衰患者中,较高基线[68Ga]FAPI-46摄取与优化药物治疗后射血分数改善较少相关(r = -0.52;P = .02)。
临床怎么用
- [68Ga]FAPI-46 PET/MRI可无创显示心衰患者心肌成纤维细胞活化的空间模式,有助于病因表型区分与风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adverse myocardial remodeling and fibrosis contribute to heart failure progression and are thought to be driven by activated fibroblasts. Noninvasive assessment of myocardial fibroblast activation may improve phenotyping and risk stratification in heart failure. OBJECTIVE: To evaluate myocardial fibroblast activation in patients with heart failure with reduced ejection fraction using gallium 68-labeled fibroblast activation protein inhibitor 46 ([68Ga]FAPI-46) positron emission tomography (PET) and magnetic resonance imaging (MRI). DESIGN, SETTING, AND PARTICIPANTS: This was a prospective case-control study including patients with heart failure with reduced ejection fraction, patients with prior myocardial infarction without heart failure, and healthy volunteers. A subset of patients with heart failure underwent repeat imaging after more than 6 months. Data analysis was conducted from January 2024 to January 2025. EXPOSURE: All participants underwent [68Ga]FAPI-46 PET/MRI. MAIN OUTCOMES AND MEASURES: Myocardial fibroblast activation quantified using maximum standardized uptake values (SUVmax) of [68Ga]FAPI-46. RESULTS: A total of 81 participants were included (mean [SD] age, 66.2 [9.7] years; 22 [27%] female): 42 with heart failure (21 with heart failure due to ischemic cardiomyopathy from a previous myocardial infarction and 21 with a nonischemic etiology; mean [SD] left ventricular ejection fraction, 41% [9%]), 20 with a prior myocardial infarction but preserved left ventricular systolic function, and 19 healthy volunteers. No myocardial fibroblast activation was observed in healthy volunteers. All patients with heart failure demonstrated increased myocardial [68Ga]FAPI-46 uptake compared with healthy volunteers (mean [SD] SUVmax, 2.7 [1.5] vs 1.5 [0.3]; P < .001). Uptake was highest in patients with ischemic cardiomyopathy, localizing to regions of established myocardial infarction (mean [SD] SUVmax, 3.2 [1.1]). Patients with nonischemic cardiomyopathy exhibited a different pattern of diffuse, lower-intensity uptake (mean [SD] SUVmax, 2.3 [0.5]), with the highest signal in the basal septum irrespective of late gadolinium enhancement. Patients with ischemic cardiomyopathy had higher uptake than patients with prior myocardial infarction without heart failure (n = 20) despite no major difference in infarct size (mean [SD] SUVmax, 3.2 [1.1] vs 2.5 [0.3]; P = .03). Among patients with heart failure who underwent repeat imaging, higher baseline [68Ga]FAPI-46 uptake was associated with less improvement in ejection fraction with optimal medical therapy over time (r = -0.52; P = .02). CONCLUSIONS AND RELEVANCE: In this case-control study, patients with heart failure demonstrated persistent myocardial fibroblast activation with distinct spatial patterns according to cardiomyopathy etiology. Noninvasive imaging of fibroblast activation may provide mechanistic insights, aid risk stratification, and support the development of targeted antifibrotic therapies in heart failure.
引用
- Joshi SS, Barton AK, Loganath K, et al. Myocardial Fibroblast Activation in Ischemic and Nonischemic Cardiomyopathy. JAMA Cardiol. 2026. PMID: 41984469. doi:10.1001/jamacardio.2026.0661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。